Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A molecular model on a lab table with a research notebook.

Jul 1, 2026

Mankind Pharma partners with Denovo Sciences to drive AI-led innovation in drug discovery

Mankind Pharma has entered a strategic partnership with Denovo Sciences to enhance drug discovery through AI innovation.This collaboration aims to leverage Mankind Pharma's robust research and development capabilities alongside Denovo Sciences' advanced AI platform for molecular generation and prioritization. By adopting a human-in-the-loop approach, the partnership will ensure that AI-generated candidates are rigorously evaluated and refined by scientific experts throughout the process.The init
A hand holding a notebook in a lab setting, symbolizing collaboration in drug discovery.

Jul 1, 2026

Mankind Pharma collaborates with Armenian Denovo Sciences for AI-led drug discovery programme

Mankind Pharma has partnered with Armenian startup Denovo Sciences to implement an AI-driven drug discovery initiative.This collaboration aims to merge Mankind's extensive research and development capabilities with Denovo's advanced AI platform, which focuses on molecular generation and prioritization. The partnership will employ a human-in-the-loop approach, where AI will generate and assess molecular candidates, while experts will oversee, validate, and refine these results throughout the proc
Silhouette of a human head with a geometric brain, representing AI and human collaboration in drug discovery.

Jul 1, 2026

Mankind Pharma Partners With Denovo Sciences For AI-Driven Drug Discovery

Mankind Pharma has partnered with Denovo Sciences to leverage AI in drug discovery, aiming for quicker development and reduced R&D costs.This collaboration introduces a "human-in-the-loop" approach, where AI-generated molecular research is validated by Mankind Pharma’s experts. This model intends to enhance the efficiency of early-stage research by using Denovo's AI platform to identify and prioritize potential drug candidates, ultimately streamlining the lengthy and costly drug development proc
An open research notebook with a pencil in a dimly lit lab

Jul 1, 2026

Mankind Pharma Ne AI Ko Diya Hath, Drug Discovery Mein Speed Badhegi!

Mankind Pharma has entered a strategic partnership with Denovo Sciences to leverage AI in drug discovery, aiming to enhance research efficiency and reduce costs.This collaboration, announced recently, focuses on accelerating early-stage research through Denovo's AI platform, which will help identify and rank potential drug candidates. By utilizing AI-driven models, Mankind Pharma aims to decrease both the time and financial resources typically required in the initial phases of drug research. The
A minimalist representation of a drug compound in a dark color scheme.

Jul 1, 2026

Mankind Pharma & Denovo Sciences Partner for AI Drug Discovery

Mankind Pharma has entered a strategic partnership with Denovo Sciences to enhance the drug discovery process through artificial intelligence.The collaboration aims to streamline research efforts, focusing on three main objectives: shortening early drug discovery timelines, enhancing the quality of lead candidates, and advancing only those candidates with the highest potential for development. By leveraging AI technology, the partners hope to minimize resources spent on less viable candidates, t
A glass vial with a colorful drug compound in a dimly lit lab

Jul 1, 2026

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma has partnered with Denovo Sciences to enhance drug discovery through artificial intelligence.This collaboration focuses on leveraging AI technologies to streamline the drug development process, aiming to reduce timelines and enhance the quality of drug candidates. By combining AI capabilities with human expertise, Mankind Pharma and Denovo Sciences intend to pinpoint the most promising therapeutic options more efficiently. This initiative represents a noteworthy advancement in the
A drug compound on a lab bench in a dimly lit laboratory

Jul 1, 2026

Anthropic Launches Claude Science to Court Pharma Ahead of IPO

Anthropic has introduced Claude Science, an AI platform aimed at transforming pharmaceutical research by autonomously executing tasks traditionally handled by scientists. This development signals a significant shift in how AI can streamline drug discovery processes.During a recent launch event in San Francisco, Zubair Jandali, head of Anthropic's healthcare division, highlighted that Claude Science is not merely a tool for assistance; it can independently conduct analyses, such as screening for
A laboratory flask with a blue drug compound on a wooden workbench

Jul 1, 2026

Anthropic launches AI drug discovery program, joining tech giants in betting on healthcare

Anthropic has launched an internal drug discovery initiative aimed at developing AI tools for the pharmaceutical industry, specifically targeting neglected diseases that traditional companies often overlook.During a recent event in San Francisco, Eric Kauderer-Abrams, head of life sciences at Anthropic, emphasized the importance of integrating their AI development with real-world drug discovery efforts. He stated that the company believes in the value of direct experience and feedback from the d
A minimalist illustration of a pill and capsule on a dark background.

Jul 1, 2026

AI company Anthropic announces it will begin developing drugs of its own

Anthropic, a prominent AI company, has announced plans to venture into drug development, marking a significant step beyond its established role in artificial intelligence technology.During a recent event in San Francisco, Anthropic revealed its intention to explore drug development, although the specifics regarding commercialization remain uncertain. This initiative stems from a desire to apply its AI capabilities to address tangible scientific challenges. Eric Kauderer-Abrams, the head of life
A vial of a drug compound on a lab bench with chemical reagents in the background.

Jul 1, 2026

Anthropic launches in-house AI drug discovery program to target neglected diseases

Anthropic is embarking on a new internal initiative to develop AI-driven drug discovery specifically targeting neglected diseases, aiming to fill gaps left by traditional biopharmaceutical companies.The company recently announced its plans during a San Francisco event, emphasizing its commitment to create artificial intelligence tools tailored for the pharmaceutical sector. By directly engaging in drug discovery, Anthropic intends to gain firsthand experience that will inform the development of
Flat illustration of a protein structure and a molecule in a minimalist style.

Jun 30, 2026

NVIDIA Partners With Anthropic to Bring GPU-Powered AI to Life Sciences

NVIDIA has partnered with Anthropic to enhance AI-driven drug discovery through the integration of its BioNeMo Agent Toolkit into Anthropic's Claude Science platform, enabling life sciences researchers to harness GPU-accelerated computing via conversational AI.This collaboration aims to streamline complex biological research tasks, such as protein folding simulations and molecular design, by allowing researchers to interact with the technology using plain language. With this integration, tasks t
Minimalist representation of a network node for AI training centers

Jun 30, 2026

Algorae named launch partner for healthcare in new Sovereign AI Infrastructure initiative

Algorae Pharmaceuticals has been named a foundational partner for the Sovereign AI Infrastructure initiative, focusing on healthcare and life sciences. This initiative, spearheaded by AgenticScale.ai and utilizing NVIDIA-accelerated technology, aims to create a network of secure AI training and deployment centers for regulated sectors.The Sovereign AI Infrastructure (SAII) is designed to support critical industries such as healthcare, energy, and defense by providing a trustworthy environment fo